British journal of haematology

Keyphrases

Publications

volume 203, number 1, 2023

James B Bussel
A tribute to Paul Imbach. British journal of haematology 203 (1) (2023)
James L Zehnder, James B Bussel, Nichola Cooper
The role of genetics in refractory immune thrombocytopenia. British journal of haematology 203 (1) (2023)
Bertrand Godeau
Is splenectomy a good strategy for refractory immune thrombocytopenia in adults? British journal of haematology 203 (1) (2023)
Paul Imbach, John W Semple
In Memoriam Robert McMillan. British journal of haematology 203 (1) (2023)
David J Kuter, Ellis J Neufeld
Novel therapeutics and future directions for refractory immune thrombocytopenia. British journal of haematology 203 (1) (2023)
Ilene Ceil Weitz, Howard Allen Liebman
Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP. British journal of haematology 203 (1) (2023)
Alexandra Schifferli, Axel Rüfer, Alicia Rovo, Falk Nimmerjahn, Nathan Cantoni, Andreas Holbro, Geneviève Favre, Jan Dirks, Anna Wieland, Heike Faeth, Renata Pereira, Thomas Kühne
Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. British journal of haematology 203 (1) (2023)
Douglas B Cines
Pathogenesis of refractory ITP: Overview. British journal of haematology 203 (1) (2023)
Paul Imbach, Alexandra Schifferli, Thomas Kühne
Introduction to the special issue: Refractory ITP. British journal of haematology 203 (1) (2023)
Tomás José González-López, Alexandra Schifferli
Early immunomodulation in immune thrombocytopenia-A report of the ICIS meeting in Lenzerheide, Switzerland 2022. British journal of haematology 203 (1) (2023)
Nathalie Aladjidi, Thomas Pincez, Frédéric Rieux-Laucat, Diane Nugent
Paediatric-onset Evans syndrome: Breaking away from refractory immune thrombocytopenia. British journal of haematology 203 (1) (2023)
Axel Rüfer, Deirdra R Terrell
Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP. British journal of haematology 203 (1) (2023)
Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thomas Kühne
Chronic refractory immune thrombocytopenia in adolescents and young adults. British journal of haematology 203 (1) (2023)
Guillaume Moulis, Lamya Garabet
Markers of refractory primary immune thrombocytopenia. British journal of haematology 203 (1) (2023)
Karina Yazdanbakhsh, Drew Provan, John W Semple
The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia. British journal of haematology 203 (1) (2023)

volume 202, number 3, 2023

William A Lester, Niki Walker, Kailash Bhatia, Etienne Ciantar, Anita Banerjee, Joanna Trinder, Julia Anderson, Kenneth Hodson, Lorna Swan, Charlotte Bradbury, Juliette Webster, Clare Tower
British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves. British journal of haematology 202 (3) (2023)

volume 202, number 4, 2023

Simon Stern, Satarupa Chaudhuri, Mark Drayson, Sarah Henshaw, Kamaraj Karunanithi, Fenella Willis, null null
Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. British journal of haematology 202 (4) (2023)

volume 201, number 5, 2023

Richard L Soutar, Wendy McSporran, Tracey Tomlinson, Catherine Booth, Sharran Grey
Guideline on the investigation and management of acute transfusion reactions. British journal of haematology 201 (5) (2023)
Richard L Soutar, Wendy McSporran, Tracey Tomlinson, Catherine Booth, Sharran Grey
Guideline on the investigation and management of acute transfusion reactions. British journal of haematology 201 (5) (2023)

volume 201, number 6, 2023

BarbaraJ J Bain, Yvonne Daniel, Joan Henthorn, Barbara de la Salle, Amanda Hogan, Noémi B A Roy, Ciaran Mooney, Lisa Langabeer, David C Rees, null null
Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline: A British Society for Haematology Guideline. British journal of haematology 201 (6) (2023)

volume 200, number 5, 2023

volume 200, number 6, 2023

Daisuke Minakata, Shin-Ichiro Fujiwara, Daizo Yokoyama, Atsuto Noguchi, Shuka Aoe, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. British journal of haematology 200 (6) (2023)
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R Scheffer Cliff
The promise and harms of screening for plasma cell dyscrasias. British journal of haematology 200 (6) (2023)
Yingying Zhang, Yuxin Wang
Can circulating CD34 + cell count be used for the prognosis of myelofibrosis? British journal of haematology 200 (6) (2023)
Alessandra Iurlo, Nicole Galli, Cristina Bucelli, Silvia Artuso, Dario Consonni, Daniele Cattaneo
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib. British journal of haematology 200 (6) (2023)
Solano de la Asunción Carlos, Estela Giménez, Juan Carlos Carlos Hernández-Boluda, María José Terol, Eliseo Albert, Javier López-Jiménez, Valentín García-Gutiérrez, Rafael Andreu, Dolores García, María Laura Fox, María José Remigia, Paula Amat, Carlos Solano, Davide Navarro
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. British journal of haematology 200 (6) (2023)
Solano de la Asunción Carlos, Estela Giménez, Juan Carlos Carlos Hernández-Boluda, María José Terol, Eliseo Albert, Javier López-Jiménez, Valentín García-Gutiérrez, Rafael Andreu, Dolores García, María Laura Fox, María José Remigia, Paula Amat, Carlos Solano, Davide Navarro
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. British journal of haematology 200 (6) (2023)
Dimitris A Tsitsikas, Susan Rowe, Alessandra Bosch, Caitlyn Hui, Nandini Sadasivam, Nicolaos J Palaskas, Shivan Pancham, Syed Rizvi, Joseph Taylor, Paul Greaves, Andreas Glenthoej, Marianne Hoffmann, Emma Drasar, Perla Eleftheriou
Addition of plasma exchange to red cell exchange improves outcomes of fat embolism syndrome in sickle cell disease. British journal of haematology 200 (6) (2023)
Luciano José Megale Costa, Smith Giri, Susan Bal, Gayathri Ravi, Kelly N Godby
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma. British journal of haematology 200 (6) (2023)
John-John B Schnog, Michael J Samson, Ashley J Duits
An analytical view of the BJH publication of 'a clinician's view of voxelotor'. British journal of haematology 200 (6) (2023)
Solano de la Asunción Carlos, Estela Giménez, Juan Carlos Carlos Hernández-Boluda, María José Terol, Eliseo Albert, Javier López-Jiménez, Valentín García-Gutiérrez, Rafael Andreu, Dolores García, María Laura Fox, María José Remigia, Paula Amat, Carlos Solano, Davide Navarro
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. British journal of haematology 200 (6) (2023)
Luciano José Megale Costa, Smith Giri, Susan Bal, Gayathri Ravi, Kelly N Godby
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma. British journal of haematology 200 (6) (2023)
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R Scheffer Cliff
The promise and harms of screening for plasma cell dyscrasias. British journal of haematology 200 (6) (2023)
John-John B Schnog, Michael J Samson, Ashley J Duits
An analytical view of the BJH publication of 'a clinician's view of voxelotor'. British journal of haematology 200 (6) (2023)
Yingying Zhang, Yuxin Wang
Can circulating CD34 + cell count be used for the prognosis of myelofibrosis? British journal of haematology 200 (6) (2023)
Bianca Clerici, Mariangela Scavone, Simone Birocchi, Chiara Aloise, Benedetta Peroni, Alessandra Negrini, Claudia Ghali, Giovanni Casazza, Gian Marco Podda
Prevalence of anti-platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines-A systematic review and meta-analysis. British journal of haematology 200 (6) (2023)
John-John B Schnog, Michael J Samson, Ashley J Duits
An analytical view of the BJH publication of 'a clinician's view of voxelotor'. British journal of haematology 200 (6) (2023)
Bianca Clerici, Mariangela Scavone, Simone Birocchi, Chiara Aloise, Benedetta Peroni, Alessandra Negrini, Claudia Ghali, Giovanni Casazza, Gian Marco Podda
Prevalence of anti-platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines-A systematic review and meta-analysis. British journal of haematology 200 (6) (2023)
Alessandra Iurlo, Nicole Galli, Cristina Bucelli, Silvia Artuso, Dario Consonni, Daniele Cattaneo
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib. British journal of haematology 200 (6) (2023)
Luciano José Megale Costa, Smith Giri, Susan Bal, Gayathri Ravi, Kelly N Godby
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma. British journal of haematology 200 (6) (2023)
Daisuke Minakata, Shin-Ichiro Fujiwara, Daizo Yokoyama, Atsuto Noguchi, Shuka Aoe, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. British journal of haematology 200 (6) (2023)
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R Scheffer Cliff
The promise and harms of screening for plasma cell dyscrasias. British journal of haematology 200 (6) (2023)
Bianca Clerici, Mariangela Scavone, Simone Birocchi, Chiara Aloise, Benedetta Peroni, Alessandra Negrini, Claudia Ghali, Giovanni Casazza, Gian Marco Podda
Prevalence of anti-platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines-A systematic review and meta-analysis. British journal of haematology 200 (6) (2023)
Daisuke Minakata, Shin-Ichiro Fujiwara, Daizo Yokoyama, Atsuto Noguchi, Shuka Aoe, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. British journal of haematology 200 (6) (2023)
Dimitris A Tsitsikas, Susan Rowe, Alessandra Bosch, Caitlyn Hui, Nandini Sadasivam, Nicolaos J Palaskas, Shivan Pancham, Syed Rizvi, Joseph Taylor, Paul Greaves, Andreas Glenthoej, Marianne Hoffmann, Emma Drasar, Perla Eleftheriou
Addition of plasma exchange to red cell exchange improves outcomes of fat embolism syndrome in sickle cell disease. British journal of haematology 200 (6) (2023)
Dimitris A Tsitsikas, Susan Rowe, Alessandra Bosch, Caitlyn Hui, Nandini Sadasivam, Nicolaos J Palaskas, Shivan Pancham, Syed Rizvi, Joseph Taylor, Paul Greaves, Andreas Glenthoej, Marianne Hoffmann, Emma Drasar, Perla Eleftheriou
Addition of plasma exchange to red cell exchange improves outcomes of fat embolism syndrome in sickle cell disease. British journal of haematology 200 (6) (2023)
Alessandra Iurlo, Nicole Galli, Cristina Bucelli, Silvia Artuso, Dario Consonni, Daniele Cattaneo
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib. British journal of haematology 200 (6) (2023)
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R Scheffer Cliff
The promise and harms of screening for plasma cell dyscrasias. British journal of haematology 200 (6) (2023)
Yingying Zhang, Yuxin Wang
Can circulating CD34 + cell count be used for the prognosis of myelofibrosis? British journal of haematology 200 (6) (2023)